The β1-adrenergic receptor in heart failure and beyond
When you think of how the heart adapts to stress, the β1-adrenergic receptor (β1AR) is usually the first thing that comes to mind. It's central to how the body boosts cardiac output under pressure. However, in heart failure, β1AR is implicated in accelerated decline, arrhythmia risk, and even structural remodeling. Now, researchers are exploring β1AR far beyond the heart, uncovering roles in inflammation, nephrology, and neurological disease.
A key driver of cardiac function
β1AR is the most abundant beta-adrenergic receptor in the heart. It responds to hormones like norepinephrine and adrenaline, triggering a cascade that boosts contractility and heart rate via the cAMP–PKA pathway1. This helps the heart meet increased demands during physical or emotional stress. In healthy individuals, β1AR signaling is tightly controlled: activated briefly during stress, and reset quickly. But in disease states, this balance shifts.
The β1-adrenergic receptor in heart failure
In heart failure, the body’s first response to declining cardiac output is to activate the sympathetic nervous system, leading to chronic β1AR stimulation. Initially, this helps to restore cardiac output, but prolonged activation quickly becomes maladaptive. The constant stimulation of β1AR leads to desensitization, internalization, and downregulation of the receptor2. This limits the heart’s ability to respond to further stress and disrupts calcium cycling, increasing the risk of arrhythmias.
β-blockers are a cornerstone of heart failure treatment precisely because they interrupt this harmful cycle of chronic β1AR stimulation. By competitively inhibiting β1AR activation, these drugs reduce heart rate, lower myocardial oxygen demand, and help stabilize calcium cycling. Over time, they can even reverse some of the receptor downregulation seen in heart failure, improving the heart’s ability to respond to sympathetic input3.
The broader impact of β1-adrenergic receptors
β1AR’s role extends beyond cardiomyocytes. Chronic signaling also affects cardiac fibroblasts and immune pathways. A key player here is the NLRP3 inflammasome, a protein complex activated in response to stress and damage signals. Studies have shown that prolonged β-adrenergic stimulation can activate NLRP3 in fibroblasts, leading to increased fibrosis and inflammation4. The result is structural remodeling of the heart: stiffening of the myocardium, reduced compliance, and impaired function. These findings have spurred interest in β1AR as a contributor not just to pump failure, but to the inflammatory and fibrotic processes that underpin disease progression.
β1-adrenergic receptor polymorphisms
Genetic variation in the gene encoding for β1AR (ADRB1) influences how individuals respond to both stimulation and therapy. Studies show that polymorphisms in ADRB1 can lead to changes in vulnerability to heart failure and response to β-blockers, creating a promising research area for personalized therapy5,6.
Translational models such as human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) or genetically modified mice are integral to exploring these polymorphisms in a controlled setting. Advances in iPSC-CMs have made it possible to study β1AR responses in a human-relevant system that retains the donor’s genetic background7, while humanized mouse models expressing specific ADRB1 variants have helped uncover how polymorphisms can influence cardiac outcomes under stress8.
Biased agonism and internalization
β1AR doesn’t just turn “on” or “off.” Different downstream pathways can be activated depending on the ligand — a concept known as biased agonism. This opens up the possibility of designing drugs that preserve beneficial signaling while avoiding harmful effects. One example of biased agonist activity is the β-blocker carvedilol which blocks the G-protein pathway but promotes β–arrestin–mediated cardioprotective pathways9. Researchers are now exploring whether new biased ligands could fine-tune β1AR signaling in a way that supports heart function without triggering desensitization or cell stress3.
β1AR internalization is also part of this story. When overstimulated, the receptor is pulled into the cell, reducing its availability on the surface. But internalized β1AR can still signal from endosomes, suggesting that where the receptor signals from matters, not just whether it’s active10. These mechanisms are being explored not only in heart failure but across other organs and disease states where β1AR plays a role.
β1-adrenergic receptors beyond heart failure
While heart failure remains the most studied context for β1AR, emerging research points to broader relevance:
● Arrhythmias: β1AR overstimulation disrupts calcium handling and can trigger ventricular arrhythmias. Biased ligands may offer rhythm protection without complete suppression of β1AR function11.
● Hypertension and renal disease: β1AR is expressed in the kidneys, where it regulates renin release. Its activity has implications for blood pressure control and the progression of chronic kidney disease12.
● Autoimmune and inflammatory disorders: Chronic β-adrenergic signaling is known to modulate immune cell function, including T cell and macrophage activity. β1AR antagonists may help regulate inflammation in settings like myocarditis or systemic autoimmune disease13.
● Neurological research: β1AR is also expressed in the brain, where it contributes to memory formation, mood regulation, and stress responses. There’s growing interest in its role in disorders like PTSD and anxiety, where modulating β1AR might support resilience or emotional processing14.
As new tools and models become available, including stem-cell-derived systems and targeted in vivo platforms, we’re learning that β1AR is far more than a switch for heart rate. It’s a complex modulator of cell signaling, stress response, and tissue adaptation across multiple systems.
Expanding research horizons for the β1-adrenergic receptor
β1AR is a fascinating case study: a receptor that started out as a cardiovascular drug target, but is now showing up in contexts ranging from nephrology to neurology. Its biology is rich, dynamic, and still full of open questions. Like many key signaling molecules, its true reach may only just be emerging.
References
1. Sucharov, C. C. et al. β-Adrenergic receptor stimulation and activation of protein kinase A protect against α1-adrenergic–mediated phosphorylation of protein kinase D and histone deacetylase 5. J. Card. Fail. 17, 592–600 (2011).
2. Mahmood, A., Ahmed, K. & Zhang, Y. β-Adrenergic receptor desensitization/down-regulation in heart failure: a friend or foe? Front. Cardiovasc. Med. 9, 925692 (2022).
3. Nibley, P. C. & Shenoy, S. K. β-Adrenergic receptor signaling mediated by β-arrestins and its potential role in heart failure. Curr. Opin. Physiol. 37, 100723 (2024).
4. Liu, Y. et al. The NLRP3 inflammasome in fibrosis and aging: the known unknowns. Ageing Res. Rev. 79, 101638 (2022).
5. Si, D. et al. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol. J. Cardiovasc. Pharmacol. 64, 306–309 (2014).
6. Small, K. M. et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135–1142 (2002).
7. Vučković, S. et al. Characterization of cardiac metabolism in iPSC-derived cardiomyocytes: lessons from maturation and disease modeling. Stem Cell Res. Ther. 13, 332 (2022).
8. Luzum, J. A. et al. Association of genetic polymorphisms in the beta-1 adrenergic receptor with recovery of left ventricular ejection fraction in patients with heart failure. J. Cardiovasc. Transl. Res. 12, 280–289 (2019).
9. Ippolito, M. & Benovic, J. L. Biased agonism at β-adrenergic receptors. Cell. Signal. 80, 109905 (2021).
10. Nguyen, A. H. & Lefkowitz, R. J. Signaling at the endosome: cryo-EM structure of a GPCR–G protein–beta-arrestin megacomplex. FEBS J. 288, 2562–2569 (2021).
11. Chan, Y.-H. et al. CD44 regulates Epac1-mediated β-adrenergic-receptor-induced Ca2+-handling abnormalities: implication in cardiac arrhythmias. J. Biomed. Sci. 30, 55 (2023).
12. Sandilands, A. J., O’Shaughnessy, K. M. & Yasmin. β1-Adrenoreceptor polymorphisms and blood pressure: 49S variant increases plasma renin but not blood pressure in hypertensive patients. Am. J. Hypertens. 32, 447–451 (2019).
13. Sharma, D. & Farrar, J. D. Adrenergic regulation of immune cell function and inflammation. Semin. Immunopathol. 42, 709–717 (2020).
14. Yi, B. et al. Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders. PLOS ONE 12, e0180319 (2017).